Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.05 USD
Change Today -0.03 / -1.44%
Volume 49.6K
As of 2:58 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

nanoviricides inc (NNVC) Snapshot

Open
$2.09
Previous Close
$2.08
Day High
$2.09
Day Low
$2.05
52 Week High
06/24/14 - $4.77
52 Week Low
04/9/15 - $2.03
Market Cap
120.7M
Average Volume 10 Days
208.7K
EPS TTM
$-0.16
Shares Outstanding
58.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOVIRICIDES INC (NNVC)

Related News

No related news articles were found.

nanoviricides inc (NNVC) Related Businessweek News

No Related Businessweek News Found

nanoviricides inc (NNVC) Details

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; DengueCide, a treatment against Dengue viruses; RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in West Haven, Connecticut.

6 Employees
Last Reported Date: 02/23/15
Founded in 2005

nanoviricides inc (NNVC) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $275.0K
Chairman, President and Secretary
Total Annual Compensation: $275.0K
Chief Financial Officer
Total Annual Compensation: $108.0K
Compensation as of Fiscal Year 2014.

nanoviricides inc (NNVC) Key Developments

NanoViricides, Inc. announced delayed 10-Q filing

On 02/17/2015, NanoViricides, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

NanoViricides, Inc. Approves Amendment to its Articles of Incorporation

NanoViricides, Inc. announced that at its AGM held on January 23, 2014, the shareholders approved amendment of the company’s articles of incorporation to increase the number of authorized shares.

NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility

NanoViricides, Inc. has completed the purchase of the cGMP-compliant Manufacturing and R&D facility located in Shelton, Connecticut, from Inno-Haven, LLC. The company purchased the facility solely by repaying for the costs borne by Inno-Haven, LLC, in acquiring and renovating the property. NanoViricides now intends to move its operations to the new facility in a phased manner in order to minimize any potential impact on ongoing projects. The Company expects to manufacture its drug candidates for human clinical trials at the new facility. The 18,000 sqft building at 1 Controls Drive, Shelton, CT, was completely renovated in order to build a modern, c-GMP-compliant manufacturing facility for the production of clinical scale quantities of a wide variety of injectable nanomedicines drug substances and drug products, modern nanomedicines research and development facilities, as well as an on-site nanomedicines analysis and characterization facility. The new facility comprises a small office space, R&D Chemistry Labs, R&D Biology Labs, R&D Analytical Lab and cGMP supporting Analytical Lab, cGMP-compliant raw materials handling and dispensing area, and c-GMP compliant Clean Room Suites for nanomedicines production and product packaging processes. All of the R&D labs employ class 100,000 or cleaner air systems. The clean room suites comprise class 10,000 air quality areas as well as class 1,000 and the ultra-clean class 100 air quality areas (the class specifies the number of particles per 1,000 liters of air). This allows production and handling of nanomedicines with minimal risk of entraining foreign particles.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NNVC:US $2.05 USD -0.03

NNVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NNVC.
View Industry Companies
 

Industry Analysis

NNVC

Industry Average

Valuation NNVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOVIRICIDES INC, please visit www.nanoviricides.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.